Neutralizer A Contact Plates from Merck Millipore Improve Detection of Microorganisms in Isolators and Cleanrooms
![](/46/pdcnewsitem/03/44/22/zJVWFCcSXSNWXut.jpg)
Merck Millipore's heipha ICRplus Neutralizer A contact plates improve detection of micro-organisms on disinfected surfaces in isolators and cleanrooms. Common disinfectants may contain residues from a variety of sources that inhibit the detection of microorganisms during surface monitoring, which can lead to false negative results.
Heipha Neutralizer A ICRplus contact plates allow the detection of micro-organisms in the presence of many disinfectants, including those which cannot be sufficiently inactivated by common neutralizers, such as polysorbate 80, lecithin, histidine and thiosulfate. The medium in the plates is supplemented with a mixture of ingredients called Neutralizer A to inactivate residues of a broad range of disinfectants including polyhexamethylene biguanides and quaternary ammonium compounds. The basic medium complies with the formulation of casein soya bean digest agar according to the recommendation of the current European, Japanese and United States Pharmacopoeia.
Heipha Neutralizer A ICRplus contact plates are triple-bagged, gamma-irradiated and the only plates available that feature a two-way closure system. The closed position ensures safe transport after sampling and is suitable for aerobic incubation while the vent position provides the required gas exchange for the detection of anaerobic and microaerophilic microorganisms in specific incubation atmospheres. In addition, the clear appearance of the agar medium makes analysis easier.
The plates can be stored at room temperature and have a long shelf life of 6 months. Each heipha Neutralizer A ICRplus contact plate contains a data matrix barcode, which allows secure identification of plates and supports the "paperless" lab.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance